{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T23:04:25Z","timestamp":1770678265029,"version":"3.49.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2006,8,22]],"date-time":"2006-08-22T00:00:00Z","timestamp":1156204800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"},{"start":{"date-parts":[[2006,8,22]],"date-time":"2006-08-22T00:00:00Z","timestamp":1156204800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Bisphosphonates are mostly used in the treatment of bone metastases. They have been shown to act synergistically with other chemotherapeutic agents. It is not known, however, whether similar synergistic effects exist with radiation on breast cancer cells.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Human MCF-7 breast cancer cells were treated with up to 100 \u03bcM zoledronic acid, were irradiated with up to 800 cGy or were exposed to combinations of both treatments to determine the antiproliferative effects of zoledronic acid and radiation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Zoledronic acid and radiation caused a dose-dependent and time-dependent decrease in cell viability (approximate 50% growth inhibition values were 48 \u03bcM and 20 \u03bcM for 24 hours and 72 hours, respectively, for zoledronic acid and 500 cGy for radiation). A synergistic cytotoxic effect of the combination of zoledronic acid and radiation was confirmed by isobologram analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These data constitute the first<jats:italic>in vitro<\/jats:italic>evidence for synergistic effects between zoledronic acid and radiation. This combination therapy might thus be expected to be more effective than either treatment alone in patients with metastatic breast carcinoma.<\/jats:p><\/jats:sec>","DOI":"10.1186\/bcr1543","type":"journal-article","created":{"date-parts":[[2006,8,22]],"date-time":"2006-08-22T18:19:28Z","timestamp":1156270768000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["In vitrosynergistic cytoreductive effects of zoledronic acid and radiation on breast cancer cells"],"prefix":"10.1186","volume":"8","author":[{"given":"A Ugur","family":"Ural","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferit","family":"Avcu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammed","family":"Candir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Metin","family":"Guden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M Ali","family":"Ozcan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,8,22]]},"reference":[{"key":"1509_CR1","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s11864-005-0023-0","volume":"6","author":"A Lipton","year":"2005","unstructured":"Lipton A: Management of bone metastases in breast cancer. Curr Treat Options Oncol. 2005, 6: 161-171.","journal-title":"Curr Treat Options Oncol"},{"key":"1509_CR2","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/sj.bjc.6602694","volume":"93","author":"AU Ural","year":"2005","unstructured":"Ural AU, Avcu F: Evolving therapeutic role of bisphosphonates in multiple myeloma. Br J Cancer. 2005, 93: 267-268. 10.1038\/sj.bjc.6602694.","journal-title":"Br J Cancer"},{"key":"1509_CR3","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1172\/JCI115539","volume":"88","author":"M Sato","year":"1991","unstructured":"Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E, Rodan GA: Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest. 1991, 88: 2095-2105.","journal-title":"J Clin Invest"},{"key":"1509_CR4","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/BF02983818","volume":"78","author":"AU Ural","year":"2003","unstructured":"Ural AU, Yilmaz MI, Avcu F, Pekel A, Zerman M, Nevruz O, Sengul A, Yalcin A: The bisphosphonate zoledronic acid induces cytotoxicity in human myeloma cell lines with enhancing effects of dexamethasone and thalidomide. Int J Hematol. 2003, 78: 443-449.","journal-title":"Int J Hematol"},{"key":"1509_CR5","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.coph.2006.03.005","volume":"6","author":"FP Coxon","year":"2006","unstructured":"Coxon FP, Thompson K, Rogers MJ: Recent advances in understanding the mechanism of action of bisphosphonates. Curr Opin Pharmacol. 2006, 6: 307-312. 10.1016\/j.coph.2006.03.005.","journal-title":"Curr Opin Pharmacol"},{"key":"1509_CR6","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/j.1600-0609.2005.00427.x","volume":"74","author":"F Avcu","year":"2005","unstructured":"Avcu F, Ural AU, Yilmaz MI, Ozcan A, Ide T, Kurt B, Yalcin A: The bisphosphonate zoledronic acid inhibits the development of plasmacytoma induced in BALB\/c mice by intraperitoneal injection of pristane. Eur J Haematol. 2005, 74: 496-500. 10.1111\/j.1600-0609.2005.00427.x.","journal-title":"Eur J Haematol"},{"key":"1509_CR7","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/(SICI)1097-0215(19991008)83:2<263::AID-IJC19>3.0.CO;2-T","volume":"83","author":"S Magnetto","year":"1999","unstructured":"Magnetto S, Boissier S, Delmas PD, Clezardin P: Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. Int J Cancer. 1999, 83: 263-269. 10.1002\/(SICI)1097-0215(19991008)83:2<263::AID-IJC19>3.0.CO;2-T.","journal-title":"Int J Cancer"},{"key":"1509_CR8","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1172\/JCI118841","volume":"98","author":"G Van Der Pluijm","year":"1996","unstructured":"Van Der Pluijm G, Vloedgraven H, Van der Wee-Plas L, Lowik C, Papapoulos S: Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest. 1996, 98: 698-705.","journal-title":"J Clin Invest"},{"key":"1509_CR9","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","volume":"21","author":"LS Rosen","year":"2003","unstructured":"Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, de Souza P, Zheng M, Urbanowitz G, et al: Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial \u2013 the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 2003, 21: 3150-3157. 10.1200\/JCO.2003.04.105.","journal-title":"J Clin Oncol"},{"key":"1509_CR10","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/cncr.11892","volume":"100","author":"LS Rosen","year":"2004","unstructured":"Rosen LS, Gordon DH, Dugan W, Major P, Eisenberg PD, Provencher L, Kaminski M, Simeone J, Seaman J, Chen BL, Coleman RE: Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer. 2004, 100: 36-43. 10.1002\/cncr.11892.","journal-title":"Cancer"},{"key":"1509_CR11","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1016\/S0140-6736(00)02144-9","volume":"355","author":"PJ Hoskin","year":"2000","unstructured":"Hoskin PJ, Stratford MR, Folkes LK, Regan J, Yarnold JR: Effect of local radiotherapy for bone pain on urinary markers of osteoclast activity. Lancet. 2000, 355: 1428-1429. 10.1016\/S0140-6736(00)02144-9.","journal-title":"Lancet"},{"key":"1509_CR12","first-page":"1109","volume":"12","author":"U Vogt","year":"2004","unstructured":"Vogt U, Bielawski KP, Bosse U, Schlotter CM: Breast tumour growth inhibition in vitro through the combination of cyclophosphamide\/metotrexate\/5-fluorouracil, epirubicin\/cyclophosphamide, epirubicin\/paclitaxel, and epirubicin\/docetaxel with the bisphosphonates ibandronate and zoledronic acid. Oncol Rep. 2004, 12: 1109-1114.","journal-title":"Oncol Rep"},{"key":"1509_CR13","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S0022-3565(24)29450-7","volume":"298","author":"RJ Tallarida","year":"2001","unstructured":"Tallarida RJ: Drug synergism: its detection and applications. J Pharmacol Exp Ther. 2001, 298: 865-872.","journal-title":"J Pharmacol Exp Ther"},{"key":"1509_CR14","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1054\/bjoc.1999.1131","volume":"82","author":"SG Senaratne","year":"2000","unstructured":"Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW: Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer. 2000, 82: 1459-1468.","journal-title":"Br J Cancer"},{"key":"1509_CR15","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1097\/01.cad.0000175582.01446.6f","volume":"16","author":"JK Woodward","year":"2005","unstructured":"Woodward JK, Neville-Webbe HL, Coleman RE, Holen I: Combined effects of zoledronic acid and doxorubicin on breast cancer cell invasion in vitro. Anticancer Drugs. 2005, 16: 845-854. 10.1097\/01.cad.0000175582.01446.6f.","journal-title":"Anticancer Drugs"},{"key":"1509_CR16","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1054\/bjoc.2001.1727","volume":"84","author":"SP Jagdev","year":"2001","unstructured":"Jagdev SP, Coleman RE, Shipman CM, Rostami-H A, Croucher PI: The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer. 2001, 84: 1126-1134. 10.1054\/bjoc.2001.1727.","journal-title":"Br J Cancer"},{"key":"1509_CR17","first-page":"116","volume":"16","author":"ME Stearns","year":"1996","unstructured":"Stearns ME, Wang M: Effects of alendronate and taxol on PC-3 ML cell bone metastases in SCID mice. Invasion Metastasis. 1996, 16: 116-131.","journal-title":"Invasion Metastasis"},{"key":"1509_CR18","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1002\/ijc.20602","volume":"113","author":"HL Neville-Webbe","year":"2005","unstructured":"Neville-Webbe HL, Rostami-Hodjegan A, Evans CA, Coleman RE, Holen I: Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer. 2005, 113: 364-371. 10.1002\/ijc.20602.","journal-title":"Int J Cancer"},{"key":"1509_CR19","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.ijrobp.2004.09.065","volume":"61","author":"E Algur","year":"2005","unstructured":"Algur E, Macklis RM, Hafeli UO: Synergistic cytotoxic effects of zoledronic acid and radiation in human prostate cancer and myeloma cell lines. Int J Radiat Oncol Biol Phys. 2005, 61: 535-542. 10.1016\/j.ijrobp.2004.09.065.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1509_CR20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.lungcan.2004.06.003","volume":"47","author":"S Matsumoto","year":"2005","unstructured":"Matsumoto S, Kimura S, Segawa H, Kuroda J, Yuasa T, Sato K, Nogawa M, Tanaka F, Maekawa T, Wada H: Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines. Lung Cancer. 2005, 47: 31-39. 10.1016\/j.lungcan.2004.06.003.","journal-title":"Lung Cancer"},{"key":"1509_CR21","first-page":"3506","volume":"54","author":"L Milas","year":"1994","unstructured":"Milas L, Hunter NR, Mason KA, Kurdoglu B, Peters LJ: Enhancement of tumor radioresponse of a murine mammary carcinoma by paclitaxel. Cancer Res. 1994, 54: 3506-3510.","journal-title":"Cancer Res"},{"key":"1509_CR22","first-page":"4243","volume":"55","author":"J Sun","year":"1995","unstructured":"Sun J, Qian Y, Hamilton AD, Sebti SM: Ras CAAX peptidometric FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion. Cancer Res. 1995, 55: 4243-4247.","journal-title":"Cancer Res"},{"key":"1509_CR23","doi-asserted-by":"publisher","first-page":"15309","DOI":"10.1074\/jbc.M201253200","volume":"277","author":"X Li","year":"2002","unstructured":"Li X, Liu L, Tupper JC, Bannerman DD, Winn RK, Sebti SM, Hamilton AD, Harlan JM: Inhibition of protein geranylgeranylation and RhoA\/RhoA kinase pathway induces apoptosis in human endothelial cells. J Biol Chem. 2002, 277: 15309-15316. 10.1074\/jbc.M201253200.","journal-title":"J Biol Chem"},{"key":"1509_CR24","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1046\/j.1365-2141.2003.04437.x","volume":"122","author":"M Salomo","year":"2003","unstructured":"Salomo M, Jurlander J, Nielsen LB, Gimsing P: How myeloma cells escape bisphosphonate-mediated killing: development of specific resistance with preserved sensitivity to conventional chemotherapeutics. Br J Haematol. 2003, 122: 202-210. 10.1046\/j.1365-2141.2003.04437.x.","journal-title":"Br J Haematol"},{"key":"1509_CR25","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1002\/gcc.10296","volume":"38","author":"WG McKenna","year":"2003","unstructured":"McKenna WG, Muschel RJ: Targeting tumor cells by enhancing radiation sensitivity. Genes Chromosomes Cancer. 2003, 38: 330-338. 10.1002\/gcc.10296.","journal-title":"Genes Chromosomes Cancer"},{"key":"1509_CR26","first-page":"1727","volume":"56","author":"EJ Bernhard","year":"1996","unstructured":"Bernhard EJ, Kao G, Cox AD, Sebti SM, Hamilton AD, Muschel RJ, McKenna WG: The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts. Cancer Res. 1996, 56: 1727-1730.","journal-title":"Cancer Res"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/bcr1543.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/bcr1543\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/bcr1543.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T14:41:32Z","timestamp":1736520092000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/bcr1543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8,22]]},"references-count":26,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2006,8]]}},"alternative-id":["1509"],"URL":"https:\/\/doi.org\/10.1186\/bcr1543","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,8,22]]},"assertion":[{"value":"24 May 2006","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2006","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2006","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2006","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"R52"}}